Inflammasome activation in infected macrophages drives COVID-19 pathology

Area of Science:

• Immunology
• Virology
• Pathology

Background:

• Severe COVID-19 exhibits persistent lung inflammation, cytokine release, and sustained interferon (IFN) responses.
• A humanized mouse model (MISTRG6-hACE2) recapitulates key features of severe COVID-19 pathology.
• Interventions targeting viral replication or IFN pathways can attenuate immune hyperactivation in this model.

Purpose of the Study:

• To investigate the role of lung-resident human macrophages in driving severe COVID-19 pathogenesis.
• To elucidate the mechanisms of inflammasome activation and pyroptosis in SARS-CoV-2-infected macrophages.
• To assess the therapeutic potential of targeting inflammasome pathways in COVID-19 lung inflammation.

Main Methods:

• Utilized the MISTRG6-hACE2 humanized mouse model infected with SARS-CoV-2.
• Analyzed macrophage responses, including inflammasome activation, cytokine release (IL-1, IL-18), and pyroptosis.
• Inhibited the NLRP3 inflammasome pathway to evaluate its impact on lung pathology and viral replication.

Main Results:

• SARS-CoV-2 infection of lung macrophages triggers inflammasome activation, IL-1/IL-18 release, and pyroptosis, contributing to lung hyperinflammation.
• Inhibition of the NLRP3 inflammasome pathway reversed chronic lung pathology associated with severe COVID-19.
• Blocking inflammasome activation paradoxically increased the release of infectious SARS-CoV-2 from infected macrophages.

Conclusions:

• Lung-resident human macrophages are critical drivers of severe COVID-19 lung inflammation via inflammasome-mediated pyroptosis.
• Inflammasome activation acts as a host defense mechanism, limiting productive SARS-CoV-2 viral cycles through cytokine release and cell death.
• Targeting inflammasomes presents a complex therapeutic strategy, potentially reducing inflammation but risking increased viral shedding.